PTC CLINIC
Information for Healthcare Professionals

Proton therapy for malignant lymphomas is addressed by both domestic and international recommendations.

The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using proton radiotherapy of mediastinal lymphomas in adult patients recommend the use of stricter rules to assess the optimal irradiation technique for lymphoma patients. According to these recommendations, the use of proton radiotherapy should be considered, especially in 3 groups of patients. These are patients with an interthoracic involvement that extends below the level of the left main coronary artery, young women with the need to irradiate the armpit area, and patients after several series of chemotherapy or other oncological treatments, link: http://www.bloodjournal.org/content/132/16/1635?sso-checked=true

The American Society for Radiation Oncology (ASTRO) recommendation classifies thoracic tumors (including some lymphomas) into a group of tumors for which proton radiotherapy should be considered, link: https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2017/ASTRO-updates-insurance-coverage-recommendations-f

Foreign sources proposing proton radiotherapy as an alternative radiation technique with the potential for a more gentle approach to surrounding risk organs also include the National Comprehensive Cancer Network (NCCN) guidelines – Alliance of leading oncology centers dedicated to patient care, research and education. The recommendation is based on the current version from 2020. NCCN guideline Hodgkin v. 2.2020 and B-cell non-Hodgkin lymphomas v. 1.2020 and T-cell non-Hodgkin lymphomas v. 1.2020.

The Particle Therapy Cooperative Group (PTCOG) evidence-based review of the use of proton RT in lymphomas, which was published in the Red Journal 2017, also deals with the indication of proton therapy.